Results 131 to 140 of about 18,162 (243)

Viral Suppression Rates in Salvage Treatment With Raltegravir Improved With the Administration of Genotypic Partially Active or Inactive Nucleoside/Tide Reverse Transcriptase Inhibitors

, 2011
Alexandra U. Scherrer, Viktor von Wyl, Jürg Böni, Sabine Yerly, Thomas Klimkait, Philippe Bürgisser, Christian Garzoni, Bernard Hirschel, Matthias Cavassini, Manuel Battegay, Pietro Vernazza, Enos Bernasconi, Bruno Ledergerber, Huldrych F. Günthard   +13 more
openalex   +2 more sources

Raltegravir (RAL) in Neonates: Dosing, Pharmacokinetics (PK), and Safety in HIV-1–Exposed Neonates at Risk of Infection (IMPAACT P1110)

, 2020
Diana F. Clarke, Edward P. Acosta, Mae Cababasay, Jiajia Wang, Anne Chain, Hedy Teppler, Stephanie Popson, Bobbie Graham, Betsy Smith, Rohan Hazra, Kat Calabrese, Yvonne J. Bryson, Stephen A. Spector, Jos Lommerse, Mark Mirochnick, the IMPAACT P1110 Protocol Team   +15 more
openalex   +2 more sources

Raltegravir Non-Inferior to Nucleoside Based Regimens in SECOND-LINE Therapy with Lopinavir/Ritonavir over 96 Weeks: A Randomised Open Label Study for the Treatment Of HIV-1 Infection

, 2015
Janaki Amin, Mark Boyd, Nagalingeswaran Kumarasamy, Cecilia L. Moore, M Losso, Chidi Nwizu, Lerato Mohapi, Stephen J. Kerr, Annette H. Sohn, Hedy Teppler, Boris Renjifo, Jean‐Michel Molina, Sean Emery, David A. Cooper   +13 more
openalex   +2 more sources

Raltegravir therapy in HIV multi-experience patients: safety and efficacy [PDF]

, 2008
Paola Meraviglia, Amedeo Capetti, Stefania Merli, Francesca Mazza, Valeria Micheli, Giuliano Rizzardini   +5 more
openalex   +1 more source

Maraviroc and raltegravir [PDF]

British Journal of Clinical Pharmacology, 2009
Eline A, Dubois, Adam F, Cohen
openaire   +2 more sources

Validation of an LC-MS/MS Assay for the Simultaneous Determination of Bictegravir, Doravirine, and Raltegravir in Human Plasma [PDF]

, 2020
Amanda P. Schauer, Craig Sykes, Mackenzie L. Cottrell, Angela D. M. Kashuba   +3 more
openalex   +1 more source

Efficacy, safety, and lack of interactions with the use of raltegravir in HIV‐infected patients undergoing antineoplastic chemotherapy [PDF]

, 2014
Sara Bañón, Isabel Machuca, Susana Araújo, Ana Moreno, Maria Jesús Pérez‐Elías, Santiago Moreno, José L. Casado   +6 more
openalex   +1 more source

Association of HLA-B*53 With DRESS Syndrome in Patients Treated With Raltegravir: Two Case Reports and a Literature Review. [PDF]

Basic Clin Pharmacol Toxicol
Ramos-Del Moral C, Rodríguez Cortés P, Navares-Gómez M, Campodónico D, Almenara de Riquer S, Barrios Blandino A, Mejía-Abril G, Gómez-Fernández A, Romero Sastre O, Carles García P, Abad-Santos F.   +10 more
europepmc   +1 more source

Low incidence of acute rejection within 6 months of kidney transplantation in HIV‐infected recipients treated with raltegravir: the Agence Nationale de Recherche sur le Sida et les Hépatites Virales (ANRS) 153 TREVE trial [PDF]

, 2019
Marie Matignon, J‐D Lelièvre, A. Lahiani, K Abbassi, Dominique Desvaux, Alpha Diallo, M‐N Peraldi, A. M. Taburet, Juliette Saillard, Constance Delaugerre, Dominique Costagliola, Lambert Assoumou, Philippe Grimbert, the ANRS 153 TREVE study group   +13 more
openalex   +1 more source

An In Silico and In Vitro Approach Identified Potential Trypanothione Synthetase Inhibitors with Trypanocidal Activity. [PDF]

Molecules
Gómez-Escobedo R, Méndez-Álvarez D, Paz-González AD, Ortiz-Pérez E, Vázquez-Jiménez LK, Martínez-Vázquez AV, Delgado-Maldonado T, Quintero-Solano JM, Vázquez C, Saavedra E, Avalos-Navarro G, Vázquez K, Rivera G, Nogueda-Torres B.   +13 more
europepmc   +1 more source